Board certified in internal medicine and medical oncology, Dr. Josh Bilenker founded oncology-focused therapeutics company Loxo Oncology, Inc., in 2013. After leading the company as president and chief executive officer for six years, he guided its acquisition by Eli Lilly and Company in 2019. Since 2019, Dr. Josh Bilenker has headed oncology R&D at Eli Lilly and Company, a subsidiary Loxo Oncology, overseeing the reorganization of biology and translational research operations.

Previously, Dr. Bilenker spent several years as a medical officer with the Office of Oncology Drug Products with the U.S. Food and Drug Administration. He also serves as a senior associate with the Department of Health Policy and Management at the John Hopkins University Bloomberg School of Public Health.

A graduate of Princeton University, Dr. Bilenker holds a bachelor of arts in English. After attending Johns Hopkins University School of Medicine, he completed an internship and residency in internal medicine and medical oncology at the Hospital of the University of Pennsylvania. During his postgraduate training, Dr. Josh Bilenker designed Phase I and II clinical studies for investigational cancer therapies.